Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Current Assets (2021 - 2025)

Senti Biosciences has reported Current Assets over the past 5 years, most recently at $23.3 million for Q4 2025.

  • Quarterly results put Current Assets at $23.3 million for Q4 2025, down 60.53% from a year ago — trailing twelve months through Dec 2025 was $23.3 million (down 60.53% YoY), and the annual figure for FY2025 was $23.3 million, down 60.53%.
  • Current Assets for Q4 2025 was $23.3 million at Senti Biosciences, up from $18.2 million in the prior quarter.
  • Over the last five years, Current Assets for SNTI hit a ceiling of $143.9 million in Q2 2022 and a floor of $827152.0 in Q1 2022.
  • Median Current Assets over the past 5 years was $55.7 million (2024), compared with a mean of $53.7 million.
  • Biggest five-year swings in Current Assets: soared 9633.52% in 2023 and later crashed 78.0% in 2024.
  • Senti Biosciences' Current Assets stood at $60.2 million in 2021, then surged by 70.42% to $102.6 million in 2022, then plummeted by 30.59% to $71.2 million in 2023, then fell by 17.19% to $59.0 million in 2024, then tumbled by 60.53% to $23.3 million in 2025.
  • The last three reported values for Current Assets were $23.3 million (Q4 2025), $18.2 million (Q3 2025), and $32.5 million (Q2 2025) per Business Quant data.